A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer
Phase: I/II
Ph1/2 FIH Study to assess AVZO-021 in Pts w/ Adv Solid Tumors
A PHASE 1/2 FIRST-IN-HUMAN STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI-TUMOR ACTIVITY OF AVZO-021 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PATIENTS WITHADVANCED SOLID TUMORS (AVZO-021-1001) Read Moreabout Ph1/2 FIH Study to assess AVZO-021 in Pts w/ Adv Solid Tumors
Phase: I/II
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
Phase: I/II
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301) Read Moreabout Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
Phase: III
ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303) Read Moreabout ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
Phase: III
Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292)
A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001) Read Moreabout Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292)
Phase: III
Ph2 clinical trial of BNT327 in combo with treatment in breast cancer
A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02) Read Moreabout Ph2 clinical trial of BNT327 in combo with treatment in breast cancer
Phase: II
Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05)
A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001) Read Moreabout Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05)
Phase: III
Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast
A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657) Read Moreabout Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast
Phase: III
STAR Ph3 AZD5305 with HR+ HER2 negative advanced breast cancer (EvoPAR-Breast01)
A Randomised Open-Label Phase III Study of Saruparib (AZD5305) Plus Camizestrant versus Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of BRCA1 BRCA2 or PALB2 Mutations and Hormone Receptor-Positive HER2-Negative (IHC 0 1+ 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)(D9722C00001) Read Moreabout STAR Ph3 AZD5305 with HR+ HER2 negative advanced breast cancer (EvoPAR-Breast01)
Phase: III
Ph3 HER2/neu BC (FLAMINGO-01)
A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01) Read Moreabout Ph3 HER2/neu BC (FLAMINGO-01)
Phase: III
Ph3 study of PF-07220060 in participants over 18yrs with met Breast cancer
AN INTERVENTIONAL OPEN-LABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3) (C4391024) Read Moreabout Ph3 study of PF-07220060 in participants over 18yrs with met Breast cancer
Phase: III
Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer
An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010) Read Moreabout Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer
Phase: II
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001) Read Moreabout Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase: III
Ph3 study of standard endocrine therapy with breast cancer
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422) Read Moreabout Ph3 study of standard endocrine therapy with breast cancer
Phase: III
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH) Read Moreabout Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
Phase: III
Ph3 Study of Post-Neoadjuvant MK2870 in combo with Pembro (MK3475) with triple neg breast cancer
MK2870-012: A Phase 3 Randomized Open-label Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) At Surgery Read Moreabout Ph3 Study of Post-Neoadjuvant MK2870 in combo with Pembro (MK3475) with triple neg breast cancer
Phase: III
Ryz101 for SSTR+ ER+HER2 metastatic breast cancer
Phase 1b/2 open-label trial of 225 Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+) human epidermal growth factor receptor 2 (HER2) negative locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drug conjugates and/or chemotherapy (TRACY-1) (RYZ101-201) Read Moreabout Ryz101 for SSTR+ ER+HER2 metastatic breast cancer
Phase: I/II
Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)
Phase: III
Ph2 RO7198457 CRC ctDNA+ Post Resection
A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01) Read Moreabout Ph2 RO7198457 CRC ctDNA+ Post Resection
Phase: II/III
Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001) Read Moreabout Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST
Phase: I
Ph3 study of FOLFIRI in participants with metastatic colorectal cancer
A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002) Read Moreabout Ph3 study of FOLFIRI in participants with metastatic colorectal cancer
Phase: III
Ph2 study comparing ABBV-400 with Post adjuvant ctDNA and NED
Colorectal Cancer: A Phase 2 Randomized Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED) (M24-534) Read Moreabout Ph2 study comparing ABBV-400 with Post adjuvant ctDNA and NED
Phase: II
Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03)
SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03) Read Moreabout Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03)
Phase: III
Ph1/2 FIH Study to assess AVZO-021 in Pts w/ Adv Solid Tumors
A PHASE 1/2 FIRST-IN-HUMAN STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI-TUMOR ACTIVITY OF AVZO-021 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PATIENTS WITHADVANCED SOLID TUMORS (AVZO-021-1001) Read Moreabout Ph1/2 FIH Study to assess AVZO-021 in Pts w/ Adv Solid Tumors
Phase: I/II
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
Phase: I/II
Ph2 ZN-c3 Uterine Carcinoma
A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065) Read Moreabout Ph2 ZN-c3 Uterine Carcinoma
Phase: II
Ph3 Selin P53 Endo Carcinoma
A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042) Read Moreabout Ph3 Selin P53 Endo Carcinoma
Phase: III
Ph3 study of GOG-3104 with endometrial cancer
A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769) Read Moreabout Ph3 study of GOG-3104 with endometrial cancer
Phase: III
Ph3 study to compare the efficacy and safety of sacituzumab in subjects with endometrial cancer
MK2870-033: A Phase 3 Randomized Open-label Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT MK-2870) in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29) Read Moreabout Ph3 study to compare the efficacy and safety of sacituzumab in subjects with endometrial cancer
Phase: III
Ph1/2 FIH Study to assess AVZO-021 in Pts w/ Adv Solid Tumors
A PHASE 1/2 FIRST-IN-HUMAN STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI-TUMOR ACTIVITY OF AVZO-021 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PATIENTS WITHADVANCED SOLID TUMORS (AVZO-021-1001) Read Moreabout Ph1/2 FIH Study to assess AVZO-021 in Pts w/ Adv Solid Tumors
Phase: I/II
A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer
Phase: II
Ph1/2 FIH Study to assess AVZO-021 in Pts w/ Adv Solid Tumors
A PHASE 1/2 FIRST-IN-HUMAN STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI-TUMOR ACTIVITY OF AVZO-021 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PATIENTS WITHADVANCED SOLID TUMORS (AVZO-021-1001) Read Moreabout Ph1/2 FIH Study to assess AVZO-021 in Pts w/ Adv Solid Tumors
Phase: I/II
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
Phase: I/II
STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC
A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203) Read Moreabout STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC
Phase: I/II
Ph2 MRTX849 Pembro NSCLC KRAS
A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007) Read Moreabout Ph2 MRTX849 Pembro NSCLC KRAS
Phase: II/III
Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS)
A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012) Read Moreabout Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS)
Phase: II
Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12)
A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001) Read Moreabout Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12)
Phase: III
A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)
Phase: IIIB
Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7)
A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007) Read Moreabout Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7)
Phase: III
Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302) Read Moreabout Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
Phase: I
Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies
Phase: I
Ph2 RO7198457 CRC ctDNA+ Post Resection
A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01) Read Moreabout Ph2 RO7198457 CRC ctDNA+ Post Resection
Phase: II/III
Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080 an HLA-G Antagonist as Monotherapy and in Combination with Pembrolizumab Cetuximab or FOLFIRI plus Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001) Read Moreabout Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST
Phase: I
Ph3 study of FOLFIRI in participants with metastatic colorectal cancer
A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002) Read Moreabout Ph3 study of FOLFIRI in participants with metastatic colorectal cancer
Phase: III
Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03)
SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03) Read Moreabout Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03)
Phase: III
A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor activity of GIM-122 as a Single Agent in Adult Subjects with Advanced Solid Malignancies
Phase: I/II
Ph1/2 FIH MRTX1719 ST MTAP Deletion
A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 (BMS-986504) in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion (1719-001/CA240-0007) Read Moreabout Ph1/2 FIH MRTX1719 ST MTAP Deletion
Phase: I/II
A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors.
Phase: I
Ph1/2 FIH Study to assess AVZO-021 in Pts w/ Adv Solid Tumors
A PHASE 1/2 FIRST-IN-HUMAN STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI-TUMOR ACTIVITY OF AVZO-021 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PATIENTS WITHADVANCED SOLID TUMORS (AVZO-021-1001) Read Moreabout Ph1/2 FIH Study to assess AVZO-021 in Pts w/ Adv Solid Tumors
Phase: I/II
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
Phase: I/II
A Phase 2 Study of TL118 for the Treatment of Patients With Solid Tumors Harboring NTRK Gene Fusions
Phase: II
Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors
A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001) Read Moreabout Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors
Phase: I/II
First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor
Phase: I
nab-Sirolimus Expanded Access Protocol for Patients Previously Participating in Aadi Sponsored Clinical Trials TSC-007 (PRECISION 1), EEC-201, or NET-202
Phase: N/A